Apellis Pharmaceuticals
APLS
NASDAQ
IPO2017
about APLS
Apellis Pharmaceuticals specializes in developing innovative therapies for rare diseases, with a focus on complement disorders, including its lead product Coversyl, which treats conditions such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic anemia.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $22.13 | $24.08 | $22.02 | $2.99B | 4.34M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| +$1.71 | 165.93 | 6.59 | 48.67% | 47.04% | 0% |